Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/14/2007

bacteria exposed to antibiotics in front-loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). By examining the resistance patterns of bacteria and applying its delivery technologies, MiddleBrook has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

About Keflex:

Keflex(R) (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram- negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on Keflex and prescribing information are available at http://www.middlebrookpharma.com/products_antibiotics/keflex_antibiotics.as px.

This announcement contains historical financial information as of and for three-month and nine-month periods ended September 30, 2007 and September 30, 2006 that is unaudited, and MiddleBrook assumes no obligation to update this information based on new information or future performance except as may be specifically required by applicable law or regulation. The unaudited annual financial information is subject to audit by independent accountants on an annual basis following the close of each calendar year.

This announcement contains forward-looking statements within th
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... December 22, 2014 7,178 small business ... of Black Friday shopping and opted instead to join ... education company, for their 5th annual “Black Friday Boot ... just $7 to attend the 5 hour online training ... promptly donated to support two Central Texas based charities ...
(Date:12/22/2014)... Christmas is days away, and last minute gifts ... solution that will please: the Sublime Gift Card . ... $25 up to $350," says Kathy Heshelow, founder of ... wide array of skin care products and Skin Brushes." , ... , Gift delivery past shipping deadlines, or those last ...
(Date:12/22/2014)... OAK BROOK, Ill. (PRWEB) December 21, 2014 ... receive radiologist recommendations for chest computed tomography (CT) ... have clinically relevant findings, including cancer, according to ... Radiology. , Researchers said the findings show ... chest X-rays represent valuable contributions to patient care. ...
(Date:12/22/2014)... December 22, 2014 Parker & Sons, ... best in Arizona home contracting services reports a record ... its quality services in 2014. As a company that ... early 1970s, Parker and Sons is a business that ... company works side-by-side with other top quality companies in ...
Breaking Medicine News(10 mins):Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3
... 18 Taking Control of Your Diabetes,(TCOYD) announced ... national,research firm Yankelovich that found that more than ... think that excess weight has a positive effect ... overweight often contributes,to the development of diabetes, complicates ...
... Cross asks you to help save lives by donating ... is being held on Saturday, February 21, 2009 from ... Koerner of Sewell, New Jersey. To make an ... (1-800-448-3543). (Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO )Koerner is battling a ...
... contest for children K-5TULSA, Okla., Feb. 18 There ... sixth annual Be Smart--Don,t Start! storyboard contest, ... of tobacco use. Request free contest materials and information ... be postmarked by Feb. 27.Sponsored by the American Lung ...
... 2009 Takeda Pharmaceutical Company Limited and its wholly-owned ... the United States Food and Drug Administration (FDA) has ... the chronic management of hyperuricemia in patients with gout. ... option in more than 40 years for the more ...
... the journal Nature Genetics have for the ... heart attack and coronary heart disease. In one of ... kind, the Myocardial Infarction Genetics Consortium identified nine precise ... three of them newly discovered; the investigators said that ...
... to be an international leader in personalized medicine and ... of Canadians and to reap the benefits of job ... http://www.cmaj.ca/cgi/rapidpdf/cmaj.1090199 released online today in CMAJ ( Canadian ... based on an individual,s genetic and health needs, rather ...
Cached Medicine News:Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 3Health News:Blood Drive Held in Honor of Sewell, NJ Resident - Ellie Koerner 2Health News:Last Chance! Be Smart--Don't Start! Entries Due by Feb. 27 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 3Health News:New genomic markers associated with risk of heart disease and early heart attack 2
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
(Date:12/19/2014)... 2014 You,re visiting the dentist for what ... he or she says you need a root canal. ... may have several questions and feel apprehensive about your ... it,s nothing to worry about. The Pennsylvania Dental Association ... any anxiety the public may have surrounding this common ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2
... Inc. announced today that it has entered into ... to provide Otsuka with access to BioWa,s POTELLIGENT® ... of their antibody therapeutics with enhanced antibody-dependent cellular ... License was initiated in May, 2007 with Takeda ...
... PEAK Surgical, Inc. and Medtronic, Inc. (NYSE: MDT ... Technologies business at Medtronic exclusive rights for global distribution ... Adenoid) tissue dissection device for the ear, nose, and ... is a major step toward our goal of capturing ...
Cached Medicine Technology:BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: